Keywords
Hypolipidemic
Cholesterol
Registries
Dyslipidemia
How to Cite
Abstract
introduction: Drug use studies are important to evaluate the effectiveness and safety of drugs in daily practice, outside the controlled clinical study. Lipid-lowering drugs act on the lipid profile, decreasing the risk of cardiovascular diseases. Objective: To describe the clinical performance and safety of the use of lipid-lowering drugs in real practice in a group of patients diagnosed with dyslipidemia. Methods: An observational, descriptive cohort study. A cohort of patients with hypolipidemic indication for 6 months was followed in 12 cities of Colombia that belong to the biomedical registry of follow-up of patients treated with medicines from the Abbott portfolio. Baseline demographic and clinical variables, safety and efectivity of the drugs were measured on the lipid profile at 3 and 6 months. Results: 501 patients received lipid-lowering agents. Statins alone decreased the low density (LDL) cholesterol of 249 mg / dL (RIQ = 226-268) at baseline to 190 (177.6-210) and 170 (108-170) at the second and third measurements, respectively. For statin + ezetimibe, from 167 mg / dL (RIQ = 139-184) to 132 (110-150) and 128.5 (101.5-128.5). Fenofibrate decreased triglycerides from 275 mg / dL (RIQ = 219-346) to 201 (172-239) and 150.5 (140-150.5). Conclusions: The administration of statins alone or in combination decreased LDL and total cholesterol levels, while fenofibrate demonstrated its effectiveness in lowering triglycerides. No adverse effects were reported. There was partial adherence of the treating physician to GPC for dyslipidemias. There were no adverse events. MÉD.UIS.2019;32(1):13-20.
References
2. Ministerio de la Protección Social-Universidad Nacional de Colombia. Estudio sobre uso y prescripción de
edicamentos en cinco ciudades colombianas. Bogotá; 2005.
3. Soto-Álvarez J. Estudios observacionales para evaluar la efectividad clínica de los medicamentos. Uso de listas-guía
para su diseño, análisis e interpretación. Atención primaria. 2005;35(3):156-162.
4. Saladrigas MV, Sacristán JA. Fichas de MedTrad (n. 13): eficacia, efectividad y eficiencia en la investigación de fármacos. Panace@. 2004;5(17-18):188-190.
5. Calderón CA, Urbina A. La Farmacovigilancia en los últimos 10 años: actualización de conceptos y clasificaciones.
logros y retos para el futuro en Colombia. Med UIS. 2011; 24(1):53-66.
6. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;
(5):205-7.
7. Epstein RA. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex. Yale J Health Policy Law Ethics.2005; 5(2):741-70.
8. López-Jaramillo P, López J. Lecciones aprendidas de dos grandes estudios epidemiológicos de enfermedades cardio-cerebrovasculares en las que ha participado Colombia. Rev Colomb Cardiol. 2010; 17(5):195-200.
9. Martínez JL. Factores asociados a la mortalidad por enfermedades no transmisibles en Colombia 2008-2012. Biomédica. 2016; 36:535-46.
10. Aorca-Martinez G, López-Jaramillo P, Molina DI, Sotomayor , Accini JL., García H, et al. El aporte colombocuatoriano al estudio hopE-3 ya la prevención primaria cardiovascular. Acta Med Colomb. 2016; 41(3):60-64.
11. Schargrodsky H, Hernández R, Champagne BM, Silva H, Vinueza R, Silva LC, et al. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med. 2008; 121(1):58-65.
12. Miranda JJ, Herrera VM, Chirinos JA, Gómez LF, Perel P, Pichardo R, et al. Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American consortium of studies in obesity (LASO). PLoS One. 2013; 8(1): e54056.
13. Galvis Y, Barona J, Cardona J. Prevalencia de dislipidemias en una institución prestadora de servicios de salud de Medellín (Colombia), 2013. Rev CES Med. 2016; 30(1): 3-13.
14. Ministerio de Salud y Protección Social – Colciencias. Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias en la población mayor de 18 años. 2014[enero, 2017], Guía 27. Disponible en: http://gpc.minsalud.gov.co/gpc_sites/Repositorio/ Conv_563/GPC_dislipidemias/GPC_dislipidemias_profesionales. aspx.
15. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25): 2889-2934.
16. López-Jaramillo P, Camacho PA, Un reto para Colombia: mejorar la utilización de medicamentos probadamente beneficiosos en la prevención secundaria cardiovascular. Colombia médica. 2012; 43(1): 7-10.
17. Diaztagle JJ, Chaves WG, Sprockel JJ, Sastoque JA, Nieto JA, Barreto GA, Hernández JI. Cumplimiento de metas de lípidos, según guías ATP III en prevención secundaria en consulta externa de Medicina Interna. Acta Med Colomb.
013; 38(2): 54-60.
18. Merchan A, Jaramillo C, Mendoza F, Agudelo JF. ¿Se están alcanzando las metas en el perfil lipídico de personas con enfermedad coronaria previa? Rev Colomb Cardiol 2011; 18(5): 262-267.
19. Bellows BK, Kuo KL, Biltaji E, Singhal M, Jiao T, Cheng Y, et al. Real-world evidence in pain research: a review of data sources. J Pain Palliat Care Pharmacother. 2014;28(3):294-304.
20. Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, et al. Using registries to identify adverse events in rheumatic diseases. Pediatrics. 2013;132(5):e1384-94.
21. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidemias. E Heart J. 2016; 37(39):2999-3058.
22. Machado JE, Moncada JC, Mesa G. Patrones de prescripción de antilipémicos en un grupo de pacientes colombianos. Rev Panam Salud Pública. 2008;23(3)179–87.
23. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med. 2008;359(21):2195-207.
24. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin egimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-87.
25. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on
cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366:1849–1861.
26. Machado-Alba JE, Machado-Duque ME, Yepes MC, Manrique S, Tobón LM. Tratamiento hipolipemiante y su efectividad en pacientes de cuatro ciudades colombianas. Acta Med Colomb. 2016; 41: 181-186.
27. Vanegas A, Jaramillo N. Intolerancia a las estatinas, un reto en la práctica clínica. Rev Colomb Cardiol. 2008; 15(2): 75-83.
28. Waters D, Brotons C, Chiang C, Ferrières J, Foody J, Jukema J, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009;120(1):28-34.
29. Boytsov S, Logunova N, Khomitskaya Y. Suboptimal control of lipid levels: results from the non interventional
entralized Pan Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II). Cardiovasc Diabetol. 2017; 16(1):158.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2019 Revista Médicas UIS